山内 理海MASAMI YAMAUCHI

Last Updated :2021/07/02

所属・職名
病院(医) 講師
メールアドレス
myamauchihiroshima-u.ac.jp
自己紹介
がんの化学療法と支持療法を専門としています

基本情報

主な職歴

  • 2001年04月, 2003年03月, 県立広島病院, 研修医
  • 2003年04月, 2005年03月, 市立三次中央病院, 医師
  • 2005年04月, 2007年03月, 廿日市市立吉和診療所, 所長
  • 2007年04月, 2018年03月, 県立広島病院, 医師
  • 2018年04月01日, 2018年04月30日, 広島大学, 病院, 医科診療医
  • 2018年05月01日, 2019年04月30日, 広島大学, 病院, 助教
  • 2019年05月01日, 広島大学, 病院, 講師

学歴

  • 広島大学, 大学院医歯薬保健学研究科, 博士課程医歯薬学専攻医学専門プログラム, 日本, 2013年10月, 2018年02月
  • 自治医科大学, 医学部, 医学科, 日本, 1995年04月, 2001年03月

学位

  • 博士(医学) (広島大学)

研究分野

  • 医歯薬学 / 内科系臨床医学 / 消化器内科学

研究キーワード

  • がん教育
  • がん治療

所属学会

  • 日本臨床腫瘍学会
  • 日本消化器病学会
  • 日本内科学会
  • 日本超音波医学会
  • 日本癌学会

教育活動

授業担当

  1. 2021年, 修士課程・博士課程前期, セメスター(前期), 病態生理学

研究活動

学術論文(★は代表的な論文)

  1. ★, Serial profiling of circulating tumor DNA for optimization of anti-VEGF chemotherapy in metastatic colorectal cancer patients, Int J Cancer, 142巻, 7号, pp. 1418-1426, 2018
  2. Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study), Int J Clin Oncol, 24巻, 10号, pp. 1223-1230, 20190529
  3. Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis, HEPATOLOGY COMMUNICATIONS, 3巻, 3号, pp. 348-355, 201903
  4. Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice, JOURNAL OF GASTROENTEROLOGY, 54巻, 7号, pp. 650-659, 201907
  5. Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt, CLINICAL JOURNAL OF GASTROENTEROLOGY, 12巻, 4号, pp. 341-346, 201908
  6. Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib, ONCOLOGY, 97巻, 2号, pp. 75-81, 2019
  7. Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy, SCIENTIFIC REPORTS, 9巻, 20190820
  8. Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis, J Gastroenterol, 20巻, 20190904
  9. Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy, Clin J Gastroenterol, 20190828
  10. 肝細胞癌のゲノム医療を目指して ①liquid biopsy, The Liver Cancer Journal, 11巻, 1号, pp. 20-24, 201903
  11. Long-term survival of a patient with stage IV basaloid squamous carcinoma of the esophagus with lung metastases following combined modality therapy, Nihon Shokakibyo Gakkai Zasshi, 112巻, 8号, pp. 1503-1509, 201508
  12. Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection, EUROPEAN JOURNAL OF RADIOLOGY, 124巻, 202003
  13. Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection, INTERNAL MEDICINE, 59巻, 7号, pp. 941-944, 2020
  14. Isolated cardiac metastases of hepatocellular carcinoma after resection: a case report, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13巻, 3号, pp. 421-427, 202006
  15. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib, THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 12巻, 202005
  16. Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab, HEPATOLOGY RESEARCH, 50巻, 7号, pp. 885-888, 202007
  17. Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma, CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 11巻, 202005
  18. Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 35巻, 8号, pp. 1412-1419, 202008

招待講演、口頭・ポスター発表等

  1. TUMOR AND BLOOD FGFR4 LEVELS PREDICT THE EFFICACY OF LENVATINIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA, Masami Yamauchi, Atsushi Ono, Haruna Hatooka, Kenichiro Kodama, Peiyi Zhang, Yuji Teraoka, Kei Morio, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Daiki Miki, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Clair Nelson Hayes, Hiroshi Aikata, Kazuaki Chayama, The Liver Meeting 2019, American Association for the Study of Liver Diseases, 2019年11月09日, 通常, 日本語
  2. REVERCE: Randomized Phase II Study of Regorafenib Followed by Cetuximab vs. Reverse Sequence for Colorectal Cancer, Masami Yamauchi, Kohei Shitara, Takeharu Yamanaka, Tadamichi Denda, Yasushi Tsuji, Yoshito Komatsu, Yoshimitsu Kobayashi, Junji Furuse, Takeshi Kato, Eiji Oki, Takashi Ando, Yasuhiro Hagiwara, Yasuo Ohashi, Takayuki Yoshino, 2018 the Japanese Society of Medical Oncology Annual Meeting, 2018年07月19日, 通常, 日本語, 神戸市
  3. 次世代シーケンサーを用いた大腸がん化学療法中のcirculating tumor DNA追跡, 第104回日本消化器病学会総会, 2018年04月19日, 通常, 日本語, 東京都
  4. Serial profiling of circulating tumor DNA identifies biomarkers for anti-VEGF chemotherapy in mCRC patients, Yamauchi, Masami; Chayama, Kazuaki; Urabe, Yuji; Ono, Atsushi; Ochi, Hidenori; Miki, Daiki, 第15回日本臨床腫瘍学会学術集会, 2017年07月, 通常, 日本語
  5. A COMPREHENSIVE ANALYSIS OF A WIDE RANGE OF LIVER DISEASES BY 16S rRNA SEQUENCING REVEALS CHARACTERISTIC PATTERNS OF GUT MICROBIOTA IN EACH ETIOLOGY, Daiki Miki, Yumi Shimomura, Nelson Hayes, Hiromi Abe-Chayama, Hatsue Fujino, Maiko Numba, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Grace Naswa Makokha, Tatsuhiko Tsunoda, Kazuaki Chayama, The Liver Meeting 2019, American Association for the Study of Liver Diseases, 2019年11月11日, 通常, 英語
  6. INDEPENDENT IMPACT OF POLYMORPHISM IN IRF5 AS WELL AS STAT4 ON HBV-RELATED HEPATOCARCINOGENESIS, Daiki Miki, Masataka Tsuge, Hiromi Abe-Chayama, Nelson Hayes, Hatsue Fujino, Grace Naswa Makokha, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Tatsuhiko Tsunoda, Kazuaki Chayama, The Liver Meeting 2019, American Association for the Study of Liver Diseases, 2019年11月11日, 通常, 英語
  7. ASSOCIATION OF FNDC5, PNPLA3 AND TM6SF2 POLYMORPHISMS WITH HEPATIC STEATOSIS IN NAFLD PATIENTS, Daiki Miki, Takashi Nakahara, Eisuke Murakami, Hiromi Abe-Chayama, Hatsue Fujino, Atsushi Ono, Masami Yamauchi, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Nelson Hayes, Grace Naswa Makokha, Tatsuhiko Tsunoda, Kazuaki Chayama, The Liver Meeting 2019, American Association for the Study of Liver Diseases, 2019年11月10日, 通常, 英語
  8. DIFFERENTIAL EFFECTS OF HOST GENETIC FACTORS ON HCV PERSISTENCE ACCORDING TO HCV GENOTYPES, Daiki Miki, Tomokazu Kawaoka, Nelson Hayes, Hiromi Abe-Chayama, Hatsue Fujino, Grace Naswa Makokha, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Tatsuhiko Tsunoda, Kazuaki Chayama, The Liver Meeting 2019, American Association for the Study of Liver Diseases, 2019年11月10日, 通常, 英語
  9. PERMISSION OF HEPATITIS B VIRUS INFECTION IN Jak3KORag2KO MOUSE, Yuji Teraoka, Michio Imamura, Takuro Uchida, Kazuki Ohya, Mitsutaka Osawa, Kei Morio, Hatsue Fujino, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Masataka Tsuge, Daiki Miki, Akira Hiramatsu, Hiromi Abe-Chayama, Nelson Hayes, Yuji Ishida, Chise Tateno, Hiroshi Aikata, Kazuaki Chayama, The Liver Meeting 2019, American Association for the Study of Liver Diseases, 2019年11月09日, 通常, 英語
  10. GENETIC POLYMORPHISM OF IP-10, NOT IFNL4 OR HLA-DPS, AFFECTS LIVER INFLAMMATION IN CHRONIC HEPATITIS B PATIENTS, Daiki Miki, Masataka Tsuge, Hiromi Abe-Chayama, Nelson Hayes, Hatsue Fujino, Grace Naswa Makokha, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Tatsuhiko Tsunoda, Kazuaki Chayama, The Liver Meeting 2019, American Association for the Study of Liver Diseases, 2019年11月08日, 通常, 英語
  11. EXPLORATORY ANALYSIS OF BIOMARKERS ASSOCIATED WITH CLINICAL OUTCOMES OF LENVATINIB IN HEPATOCELLULAR CARCINOMA, Atsushi Ono, Hiroshi Aikata, Masami Yamauchi, Kenichiro Kodama, Daiki Miki, Waka Ohishi, Yuji Teraoka, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Tomokazu Kawaoka, Hiromi Abe-Chayama, Masataka Tsuge, Michio Imamura, Clair Nelson Hayes, Kazuaki Chayama, The Liver Meeting 2019, American Association for the Study of Liver Diseases, 2019年11月08日, 通常, 英語
  12. IRF5高発現に関連するSNPアレルはHBV関連肝癌の発症リスクを低下させる, 三木大樹、柘植雅貴、山内理海、大野敦司、相方浩、角田達彦、茶山一彰, 第78回日本癌学会学術総会, 日本癌学会, 2019年09月26日, 通常, 日本語
  13. 膵癌患者の血中exosome のテトラスパニン発現プロファイル, 辰川裕美子、三木大樹、芹川正浩、池本珠莉、平野哲朗、吹上綾美、森豪、中村真也、斎藤裕平、河村良太、津島健、栗原啓介、壷井智史、石井康隆、山内理海、茶山一彰, 第105回日本消化器病学会総会, 日本消化器病学会, 2019年05月10日, 通常, 日本語
  14. 進行肝癌におけるレンバチニブ治療のバイオマーカーの探索, 大野敦司,相方浩,児玉健一郎,山内理海,茶山一彰, 第56会日本臨床分子医学会学術集会, 2019年04月26日, 通常, 日本語, 名古屋市
  15. Multiple genetic factors affecting nonalcoholic fatty liver disease and nonalcoholic steatohepatitis-related hepatocellular carcinoma in the Japanese population, Daiki Miki, Yuichi Hiyama, Atsushi Ono, Masami Yamauchi, Masataka Tsuge, Hiroshi Aikata, Tatsuhiko Tsunoda, Kazuaki Chayama, 11th AACR-JCA Joint Conference, 2019年02月10日, 通常, 英語
  16. Association of TLL1 Polymorphism with Development of Hepatocellular Carcinoma after Hepatitis C Virus Eradication and Fibrosis Severity, Daiki Miki, Tomokazu Kawaoka, Yuko Nagaoki, Nelson Hayes, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Hiromi Abe-Chayama, Hidenori Ochi, Tatsuhiko Tsunoda, Kazuaki Chayama, The Liver Meeting 2018, American Association for the Study of Liver Diseases, 2018年11月10日, 通常, 英語
  17. 日本人における非アルコール性脂肪性肝疾患・非アルコール性脂肪肝炎関連肝細胞癌の発症に関連する宿主遺伝的要因, 三木大樹、柘植雅貴、山内理海、相方浩、茶山一彰, 第77回日本癌学会学術総会, 2018年09月28日, 通常, 日本語, 大阪市

受賞

  1. 2019年, Poster of Distinction, AASLD, TUMOR AND BLOOD FGFR4 LEVELS PREDICT THE EFFICACY OF LENVATINIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA